Antitumour necrosis factor alpha therapy reduces colectomy, corticosteroid use
Treatment with the antitumour necrosis factor alpha appears to be beneficial in paediatric and adolescent patients with ulcerative colitis (UC), leading to lower colectomy rates within a period of 5 years and termination of corticosteroid use after 12 months, as shown in a recent study.
Antitumour necrosis factor alpha therapy reduces colectomy, corticosteroid use
31 Oct 2019